Our study aimed to identify compounds that could upregulate VMAT2 levels and activity since low VMAT2 levels are associated with BMVTD, Parkinson’s disease, and depression, and high VMAT2 levels are protective for Parkinson’s disease risk in humans and neurotoxicity in rodents [8–15, 17, 18]. The gene discussed is SLC18A2; the disease is Parkinson disease.